NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Deciparticle™ Platform Validation and Sapu003 Development
Oncotelic Therapeutics published a peer-reviewed manuscript validating its Deciparticle™ nanoparticle platform through the development of Sapu003, an intravenous everolimus formulation. The platform enables delivery of poorly water-soluble drugs and is being evaluated in a Phase 1b trial for advanced mTOR-sensitive solid tumors.
Deciparticle™ is Oncotelic's proprietary nanoparticle platform designed to enable intravenous delivery of poorly water-soluble therapeutic compounds. It has been validated through the development of Sapu003, an investigational everolimus formulation.
Sapu003 is an investigational intravenous everolimus formulation developed using the Deciparticle™ platform. It is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors, in combination with exemestane, to assess safety, pharmacokinetics, and preliminary antitumor activity.
The validation was published in the peer-reviewed International Journal of Molecular Sciences.
Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication.
Beyond everolimus, the platform can be applied to other hydrophobic drug candidates, as supported by the research.
Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing.
For more information, visit Oncotelic's website at www.oncotelic.com, or the press release at https://ibn.fm/gECtl. Latest updates on OTLC are available at https://ibn.fm/OTLC.